BioSpace News Archive

BioMidwest

Zomedica Pharmaceuticals Corp. Announces NYSE American Listing Approval

Trading of the common shares on the NYSE American will not commence until after Zomedica’s Registration Statement on Form S-1 is declared effective by the U.S. Securities and Exchange Commission (the “SEC”).

November 10, 2017

·

1 min read

Business

Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly

Bierly was appointed to Aclaris Therapeutics’ board of directors on October 2015,

November 10, 2017

·

1 min read

Business

Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress

As of September 30, 2017, cash and cash equivalents totaled $96.0 million.

November 10, 2017

·

9 min read

Business

Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results

The Company’s net loss applicable to common shareholders for the three months ended September 30, 2017 was $8.9 million.

November 10, 2017

·

12 min read

Business

Hackensack University Medical Center Collaborates with Novartis on Groundbreaking Pediatric Oncology Immunotherapy Program

Hackensack Meridian Health Hackensack University Medical Center is pleased to announce participation in a groundbreaking pediatric oncology immunotherapy program, provided in collaboration with Novartis Pharma as a member of a network of certified treatment centers.

November 10, 2017

·

4 min read

Business

Glyn Edwards MBE Joins OxSonics’ Board as Non-Executive Director

OxSonics Limited today announced that Glyn Edwards is to join the board as Non-Executive Director.

November 10, 2017

·

1 min read

Business

Codexis Reports Financial Results for the Third Quarter of 2017

Total revenues for the third quarter of 2017 were $10.0 million compared with $14.9 million for the third quarter of 2016.

November 10, 2017

·

16 min read

Business

Immunovaccine Announces Third Quarter 2017 Financial Results

The net loss and comprehensive loss of $2,122,000 or $0.02 per basic and diluted share for the quarter ended September 30, 2017 was $223,000 higher than the net loss and comprehensive loss for the three months ended September 30, 2016.

November 10, 2017

·

5 min read

Drug Development

Arena Completes Full Enrollment in Etrasimod Phase II Clinical Study for Ulcerative Colitis

Arena today announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative colitis.

November 10, 2017

·

7 min read

Business

Galena Biopharma Reports Third Quarter 2017 Financial Results

Operating loss from Galena’s development programs and general and administrative expenses, classified as continuing operations, during the third quarter of 2017 was $4.5 million.

November 10, 2017

·

13 min read